Salix Pharmaceuticals Rating Reiterated by JMP Securities (SLXP)
Salix Pharmaceuticals (NASDAQ:SLXP)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a research note issued to investors on Wednesday. They currently have a $190.00 price objective on the stock, up from their previous price objective of $173.00. JMP Securities’ target price suggests a potential upside of 18.16% from the company’s current price.
Salix Pharmaceuticals (NASDAQ:SLXP) traded down 2.19% during mid-day trading on Wednesday, hitting $157.28. 3,270,002 shares of the company’s stock traded hands. Salix Pharmaceuticals has a 52-week low of $64.93 and a 52-week high of $162.38. The stock’s 50-day moving average is $134.6 and its 200-day moving average is $115.3. The company has a market cap of $10.017 billion and a P/E ratio of 178.07.
Salix Pharmaceuticals (NASDAQ:SLXP) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.59 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.69 by $0.10. The company had revenue of $382.00 million for the quarter, compared to the consensus estimate of $397.06 million. During the same quarter in the prior year, the company posted $0.87 earnings per share. The company’s quarterly revenue was up 62.3% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $6.17 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Salix Pharmaceuticals in a research note on Wednesday, August 13th. They now have a $153.00 price target on the stock. Separately, analysts at Jefferies Group downgraded shares of Salix Pharmaceuticals to a “neutral” rating in a research note on Friday, August 8th. Finally, analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Salix Pharmaceuticals in a research note on Friday, August 8th. They now have a $147.00 price target on the stock, down previously from $160.00. One analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $136.98.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.